CDC NEWS


powered by Surfing Waves


Latest News


Likely Legal, ‘Vaccine Passports’ Emerge as the Next Coronavirus Divide


07 Apr 2021

Businesses and universities want fast, easy ways to see if students and customers are vaccinated, but conservative politicians have turned “vaccine passports” into a cultural flash point.


AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis


23 Mar 2021

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favorable reactogenicity and overall safety profile


Experts Discuss COVID-19—Vaccine Questions, School Openings, and More


17 Mar 2021

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the COVID-19 pandemic. Comments have been edited for clarity.


CDC Interim Recommendations for Fully Vaccinated People


10 Mar 2021

On December 11, 2020, the US reached an extraordinary milestone in the efforts to end the COVID-19 pandemic: the Food and Drug Administration authorized emergency use of the first COVID-19 vaccine, manufactured by Pfizer-BioNTech. Since then, 2 additional COVID-19 vaccines, Moderna and Janssen (Johnson & Johnson), have received Emergency Use Authorization in the US and, as of March 8, 2021, more than 31 million people, or 9.4% of the total population, have completed a vaccination series.


Approaches for Optimal Use of Different COVID-19 Vaccines Issues of Viral Variants and Vaccine Efficacy


04 Mar 2021

The efforts of the Biden administration to accelerate rollout of COVID-19 vaccines are enabling more adults in the US to be vaccinated each week. As of February 28, 2021, an estimated more than 48 million people have received at least 1 vaccine dose.




Articles


Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults


20 Dec 2022

Question: Does baseline antihypertensive medication adherence identify individuals at risk for poor adherence during sheltering for COVID-19? Findings This cohort study assessed antihypertensive medication adherence as the proportion of days covered (PDC) from filled prescriptions claims for 6 months before and after COVID-19 sheltering guidance in a random sample of 27 318 US adults. Poor adherence (PDC < 50) during sheltering occurred in 73% with poor baseline adherence, 32% with fair baseline adherence (PDC 50-79), and 10% with good baseline adherence (PDC ≥ 80). These findings suggest that adherence-promoting interventions may be helpful irrespective of sheltering for poor baseline adherence and during sheltering for fair baseline adherence.




Changes in the Relationship Between Income and Life Expectancy Before and During the COVID-19 Pandemic, California, 2015-2021


07 Jul 2022

Key Points Question How did the first 2 years of the COVID-19 pandemic affect life expectancy in California and the relationship between census tract income and life expectancy relative to prepandemic years? Findings In this retrospective analysis of 1 988 606 deaths in California during 2015 to 2021, life expectancy declined from 81.40 years in 2019 to 79.20 years in 2020 and 78.37 years in 2021. Life expectancy differences between the census tracts in the highest and lowest income percentiles increased from 11.52 years in 2019 to 14.67 years in 2020 and 15.51 years in 2021. Meaning This ecological study of deaths in the state of California demonstrated that life expectancy declines in 2020 increased in 2021 and that the life expectancy gap by income level increased during the first 2 years of the COVID-19 pandemic relative to the pre-pandemic period.




Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3


10 May 2022

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection appeared short-lived.




Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19


20 Apr 2022

Risk of SARS-CoV-2 reinfection among unvaccinated people with prior COVID-19 is a subject of debate.1,2 We performed a survival analysis in a large US population to assess the degree and duration of protection associated with natural immunity in unvaccinated individuals.




Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster


12 Apr 2022

The risk of adolescents developing myocarditis is lower after a booster dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine than after the second dose, according to a CDC analysis of data from the Vaccine Adverse Event Reporting System (VAERS). Myocarditis is a rare but serious adverse event associated with COVID-19 mRNA vaccination. To assess whether this adverse event was also associated with booster doses administered to adolescents, the authors analyzed reports submitted to the VAERS system and v-safe between December 9, 2021, and February 20, 2022.




Enroll for Free